Rite Aid Corporation (RAD) is scheduled to report second quarter 2019 earnings on Thursday. Analysts expect the company to report revenues of $5.37 billion, down 30% year-over-year, along with a loss of $0.01 per share.
Weakness in the generic drug market has been negatively impacting the stock, which does not present a positive picture to investors. Generic drug purchasing efficiencies are expected to be lower by around $80 million than when Rite Aid first charted its fiscal year 2019 guidance.
Last month, Rite Aid also terminated its merger agreement with Albertsons Companies Inc. and committed itself to executing its strategic plan as a standalone company. The company’s plan to leverage its retail pharmacies, health and wellness offerings along with its EnvisionRxOptions PBM provides some optimism though.
The company has missed estimates twice in the recent past and despite optimism on its strategic plan, the generic drug market conditions have dampened the sentiment surrounding the stock and there is a chance that Rite Aid might not bring a positive surprise this quarter. The stock has dropped 15% over the past one month.
During the first quarter, the company had posted a profit of $214.4 million or $0.20 per share, driven by one-time gains from the sale of its stores to Walgreens Boots Alliance (WBA). Net loss from continuing operations came in at $0.04 per share as a result of higher lease termination and impairment charges.
Total revenues in the first quarter fell 2% to $3.9 billion primarily due to store closures while revenues from continuing operations dropped 1% due to weaknesses in the Retail Pharmacy and Pharmacy Services segments.
For the full year of 2019, the retailer has guided for revenues of $21.7 billion to $22.1 billion with same-store sales expected to be flat to up 1%. In August, Rite Aid updated its outlook for net loss based on negative trends in the generic drug marketplace. Adjusted net loss is expected to range from $0.04 to breakeven per share versus the previous earnings range of $0.02 to $0.06 per share.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
